Exelixis Reports Encouraging Phase 1 Data for XL1...(codynamicanalyses demonstrated statistic...),Health

Date:6/1/2008

codynamic analyses demonstrated statistically significant changes at the MTD in plasma markers including VEGF-A, PlGF, and soluble VEGFR2, similar to the effects of other anti-angiogenic agents, and consistent with the anti-VEGFR activity of XL184. In addition, decreases in soluble MET were measured in 4 of 7 patients at the MTD who were analyzed for this endpoint.

"We believe the results for XL184 are remarkable and strongly support our plan to initiate a pivotal trial this summer in patients with MTC. Based on these data, we believe that XL184 is in a strong position to become the best-in-class therapy in MTC," said Michael M. Morrissey, PhD, President of Research and Development at Exelixis. "Given the potent activity of XL184 against MET, RET, and VEGFR2, and the observed long-lasting disease stabilization in a variety of tumor types in this phase 1 trial, we will continue to explore the compound's utility as a single agent, or in combination with other therapies, in tumor types like lung cancer, glioblastoma, and potentially many others."

Investor and Analyst Briefing at ASCO, Monday, June 2, 6 pm

Exelixis will host an investor and analyst briefing on Monday, June 2, at 6:00 p.m. at the Hyatt McCormick Place (Regency C&D - 2nd Floor). At this event, Exelixis will provide a review of its data presented at ASCO and describe additional data on XL147, a PI3K inhibitor, and XL281, an inhibitor of RAF. The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com. An archived replay of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on July 2, 2008. Access numbers for this replay are: 1-888-286-8010 (domestic) and +1-617-801-6888 (international); the replay passcode is: 42662164.

About XL184

XL184 inhibits MET, RET, and VEGFR2, which are key drivers of tumor growth, metastasis, survival, and angiogenesis. In phar
'/>"/>

SOURCE Exelixis, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
9. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
10. Exelixis Announces First Quarter 2008 Financial Results
11. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO